SCH 772984
Alternative Names: SCH-772984Latest Information Update: 28 May 2021
At a glance
- Originator Merck & Co
- Developer Merck & Co; University of Pittsburgh Cancer Institute; Yonsei University College of Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer